Orphan Technologies to be acquired by Retrophin for up to USD 517m
Retrophin, a San Diego, California-based biopharmaceutical company, will acquire Orphan Technologies Limited, a Swiss clinical-stage biopharmaceutical company, for up to USD 517m.
Retrophin, a San Diego, California-based biopharmaceutical company, will acquire Orphan Technologies Limited, a Swiss clinical-stage biopharmaceutical company, for up to USD 517m.